Endocrine Abstracts

Background: Zoledronic acid (ZOL) administration may cause acute phase adverse reactions (APR), which manifest with fever, malaise, bone and muscular pain, headache and/or gastrointestinal disturbances. Previous data suggest that high N-terminal propeptide of type 1 collagen (P1NP) and low 25, OH-vitaminD (VitD) levels are associated with higher incidence of APR, while the previous use of bisphosphonates is a protective factor. Lately, ZOL has been frequently used to mitigate ...

Introduction: in X-linked hypophosfatemic rickets (XLH) mutations of PHEX lead to elevated FGF-23 levels. Phosphate salts and calcitriol represented the only treatment option. Tertiary hyperparathyroidism (THPT) is a complication of XLH worsening the clinical features and constituting a contraindication to conventional treatment. Burosumab, a monoclonal antibody anti-FGF23, was recently approved in XLH. No data about Burosumab treatment in patients with XLH and THPT are availa...